Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 12/20 | 0.70 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.70 |
| ▸ | PHLPP1 | O60346 | 3/20 | 0.70 |
| ▸ | ILK | Q13418 | 3/20 | 0.70 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.58 |
| ▸ | PTGES | O14684 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18212526 | 1.00 | AKT1 (0.70) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL5771546 | 0.89 | AKT1 (0.70) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL5771699 | 0.87 | AKT1 (0.69) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL23191967 | 0.85 | AKT1 (0.66) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL6027769 | 0.85 | AKT1 (0.66) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL15042781 | 0.85 | AKT1 (0.66) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL8746281 | 0.85 | AKT1 (0.66) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL5773613 | 0.85 | AKT1 (0.73) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL8747826 | 0.85 | AKT1 (0.66) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL4677437 | 0.84 | AKT1 (0.65) | AKT1PDPK1PHLPP1ILKALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037879-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | WECHTER WILLIAM J | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037879-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | TTPA, LTA, GSTM1 | AKT1 3368/4885PDPK1 4164/4885PHLPP1 3614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.